Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Max Jaderberg, President of Isomorphic Labs, speaks to CNBC's Ritika Gupta at London Tech Week to discuss the advancement of AI in medicine Got ...
Isomorphic Labs, an AI drug discovery and development company, raised $2.1 billion in a Series B funding round led by Thrive Capital. The raise was also backed by existing investors Alphabet and GV ...
The US Court of Appeals for the Second Circuit affirmed in part and reversed in part a judgment on the pleadings, clarifying that the de minimis doctrine does not apply where the copyrighted work is ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Demis Hassabis, CEO of Isomorphic and Google DeepMind Isomorphic, which formed as an ...
May 12 (Reuters) - Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its latest funding round led by existing investor Thrive ...
If any proof was needed that big money is still available for AI drug development, look no further than the ten-figure series B hauled in by Isomorphic Labs. The London-based AI drug discovery firm ...
Isomorphic Labs raised $2.1 billion in its Series B funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas. The subsidiary of Google parent Alphabet ...
Advanced discussions are underway to raise more than $2B for Isomorphic Labs, an AI-driven drug discovery firm spun out of Alphabet's (GOOG) Google DeepMind, as part of a new funding round, Bloomberg ...
Isomorphic Labs Inc., an Alphabet Inc. unit using artificial intelligence to speed up drug development, is reportedly in talks to raise a new funding round. Sources told Bloomberg today that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results